GLP-1 Peptides Compared: Semaglutide vs Tirzepatide vs Retatrutide
Semaglutide, tirzepatide, and retatrutide are compared as if they were three strengths of one drug. They differ in receptor targets, approval status, and trial maturity. This guide compares the three honestly — including what the headlines skip.
Semaglutide, tirzepatide, and retatrutide are the three most discussed compounds in the modern metabolic research space, and they are frequently compared as if they were three strengths of the same thing. They are not. They differ in what receptors they target, how much human trial data exists, and what the trials actually measured.
This guide compares the three honestly — including the parts the hype tends to skip.
What these compounds are
All three belong to the incretin family. GLP-1 (glucagon-like peptide-1) is a natural peptide hormone involved in blood sugar regulation and appetite. Semaglutide mimics it. Tirzepatide mimics it and GIP (glucose-dependent insulinotropic polypeptide). Retatrutide mimics GLP-1, GIP, and glucagon — a triple agonist.
Two accuracy notes the comparison crowd often gets wrong:
- Tirzepatide and semaglutide are not peptides in the popular-research sense. They are large peptide-based medicines — approved drugs (Ozempic/Wegovy, Mounjaro/Zepbound) with full regulatory review behind them. For the small-molecule vs. peptide distinction, see MK-677 is not a peptide for how we draw these lines.
- Retatrutide is investigational. It is not an approved medicine anywhere; its human evidence comes from trials, with Phase 3 still underway.
Semaglutide
Semaglutide is a GLP-1 receptor agonist with a long half-life that allows weekly dosing. It has the largest mature evidence base of the three: multiple large randomized controlled trial programs (including the STEP and SUSTAIN trial families) measuring body composition, glycemic control, and cardiovascular outcomes in thousands of participants.
Reported trial findings include substantial average weight reduction versus placebo, improved glycemic measures, and — in dedicated outcome trials — cardiovascular benefit in specific populations. Reported side effects in trials were predominantly gastrointestinal (nausea, vomiting, diarrhea), with dose titration managing much of it.
Deep dive: semaglutide vs. tirzepatide.
Evidence tier: human RCTs — extensive.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist, also weekly. Its SURPASS trial program (type 2 diabetes) and SURMOUNT program (weight) were also large randomized controlled trials, with head-to-head data against semaglutide in some comparisons. Average weight changes in the highest-dose arms of the SURMOUNT trials were larger than those reported in semaglutide trials — though cross-trial comparisons between different populations and designs deserve caution.
Side-effect profile in trials was similar in kind to semaglutide, mainly gastrointestinal.
Deep dive: retatrutide vs. tirzepatide and semaglutide vs. tirzepatide.
Evidence tier: human RCTs — extensive.
Retatrutide
Retatrutide is the triple agonist (GLP-1/GIP/glucagon). Its human evidence so far comes primarily from a Phase 2 randomized controlled trial that reported average weight reductions larger than the other two compounds' trial programs at comparable timepoints, along with a Phase 3 program that is still in progress.
Two honest cautions. First, Phase 2 results come from smaller populations; the fuller picture awaits Phase 3 completion. Second, the glucagon component adds a mechanism the other two lack, which cuts both ways — more apparent effect in trials, and a profile with less long-term data behind it. The enthusiasm around it — and why it is so hyped on Reddit — is covered in the retatrutide obsession.
Evidence tier: human RCTs — Phase 2 published, Phase 3 pending.
Side by side
| Compound | Receptor targets | Approved medicine? | Human trial base |
|---|---|---|---|
| Semaglutide | GLP-1 | Yes | Large Phase 3 programs, long-term outcomes |
| Tirzepatide | GLP-1 + GIP | Yes | Large Phase 3 programs |
| Retatrutide | GLP-1 + GIP + glucagon | No (investigational) | Phase 2 published; Phase 3 underway |
Compound reference pages: semaglutide, tirzepatide, retatrutide.
What the trials do and don't establish
The trials behind these compounds measured averages in specific populations under medical supervision — screening, titration, monitoring, and in some cases, managed discontinuation. The numbers you see quoted are group means, not promises for individuals. Trial publications also report the rates at which participants discontinued due to side effects, which headline coverage rarely mentions.
None of this trial evidence describes what happens with unregulated "research grade" material of unverified composition — which is why, if your interest in these compounds is research understanding rather than personal use, the verification skill matters as much as the pharmacology. See peptide vendor safety.
The research tools
- Peptide calculator — reconstitution math for tirzepatide and retatrutide vials, no dose recommendations
- Peptide comparison tool — mechanisms, half-lives, evidence tiers
- Verified study library — the underlying trial records
The honest bottom line
All three compounds have real, large-scale human evidence — a rarity in this space. But "has trials" is the beginning of understanding, not the end. Which receptor targets, which populations, which outcomes, and at what stage of approval — that is where the actual differences live.
This guide is for educational and research purposes only. Nothing here is medical advice. These compounds have approved medical uses and should only be used as a medicine under medical supervision.
Related guides.
GHK-Cu: The Copper Peptide Your Body Already Makes
GHK-Cu occurs naturally in plasma and declines with age. Here's what studies show on skin, collagen, and wound research.
BPC-157: What the Research Actually Says
An honest look at BPC-157 studies — tendon, gut, and angiogenesis findings, what's preclinical, and where the evidence stops.
CJC-1295 + Ipamorelin: What the Research Shows
CJC-1295 and Ipamorelin are studied together for growth hormone release. Here is what the published research actually shows.
TB-500: What the Research Actually Says
TB-500 promotes cell migration and wound healing in animal studies. Here's what published research shows — and where it stops.
MOTS-c: The “Exercise Mimetic” Peptide Getting Longevity Reddit Excited
MOTS-c is the mitochondrial peptide longevity Reddit calls an exercise mimetic. Here is what the research on MOTS-c actually shows, mostly in mice so far.
Get a new guide every week.
Subscribe free and the Beginner's Guide to Peptide Research is yours instantly.